| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.14 | 0.008 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | -0.088 | 0.02 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.02 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.03 |
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | 0.28 | 0.03 |